



ASX / MEDIA RELEASE

Melbourne Australia; Thursday, 28 January 2010

Compumedics wins another major contract in Germany with the world's first high-definition PSG amplifier, the GRAEL™ HD-PSG sleep diagnostic system

Leading Australia-based medical-devices company, **Compumedics Limited (ASX: CMP)** is pleased to announce that the internationally renowned University Medical Centre (UMC) in Mannheim, Germany, which is part of the prestigious 600-year-old Heidelberg University, has chosen Compumedics' recently released, and the world's first high-definition PSG amplifier, the GRAEL™ HD-PSG sleep-diagnostic system, and Compumedics' AASM (American Association for Sleep Medicine) compliant Somté PSG V2. This sale represents approximately \$750K (€466k) for delivery in March 2010.

UMC Mannheim is the teaching hospital within the University of Heidelberg, and the sleep-diagnostic centre is considered to be one of Europe's leading sleep centres. UMC Mannheim employs over 4,500 people, including 1,200 nurses and caters to over 1,400 medical students.

The hospital has numerous collaborative affiliations with other scientific and healthcare institutions, including: the German Cancer Research Centre in Heidelberg; Heidelberg University Hospital; University of Mannheim; Mannheim University of Applied Sciences; and various other hospitals and medical facilities of the city and region.

Winning this new business at UMC Mannheim sleep-centre, which is an existing customer of Compumedics, is another major milestone for the

Compumedics' direct-sell strategy for its Germany-based sleep-diagnostics business.

Markus Rosenstingl, Business Manager for Germany and Austria, and Frank Dünkel Product, Manager for Germany, both noted, "It is also a significant endorsement of Compumedics' new world-class GRAEL™ HD-PSG sleep-diagnostic system, the world's first high-definition PSG device."

This announcement closely follows Compumedics' latest ASX release, detailing the FDA's (United States Food and Drug Administration) approval for the GRAEL™ HD-PSG/EEG system.

The decision by UMC Mannheim to choose Compumedics' new GRAEL™ HD-PSG system over products from major international competitors was primarily driven by:

- Compumedics' GRAEL™ offering the features and flexibility to meet the most demanding research applications while providing unmatched and exceptional signal quality in any clinical lab environment.
- Compumedics having the broadest range of sleep diagnostic devices covering all regulatory types I-IV of sleep product classifications in both wireless and wired configurations.
- Compumedics' proven ability to deliver world-class, premium quality, sleep diagnostic systems including the worlds first high-definition PSG amplifier, the GraeL™ PSG system.
- Compumedics' industry leading fully integrated laboratory management tool, Profusion™ Nexus™. A high productivity software package for managing all aspects of the day-to-day running of the laboratory for optimal efficiency with patient scheduling and patient data storage and retrieval.

In commenting on this significant milestone in the Company's strategy, David Burton, Executive Chairman said,

"The installation marks a further significant milestone in Compumedics' stated strategy to significantly expand its core sleep-diagnostic business in Europe with particular emphasis on Germany."

For Further information:

Mr David Burton
Executive Chairman, CEO
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Mr David Lawson
Chief Financial Officer
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Investor Relations & Media Enquires:

Mr Rod North
Managing Director
Bourse Communications Pty Ltd
Phone: +61 3 9510 8309
Mobile: +61 (0) 408 670 706

About Compumedics

Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological and Doppler blood-flow diagnostic monitoring devices. **In 1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, currently exceeding 14,000 studies with 20,000 patients scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe the products are distributed in over 50 countries. **In 1998** Compumedics was awarded the overall Australian Exporter of the Year. **In 2000** Compumedics was listed on the Australian Stock Exchange. **In 2002**, Compumedics acquired US-based Neuroscan - the world's leading supplier of instruments for brain-research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. **In 2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. **In 2004**, Compumedics acquired German-based DWL Elektronische GmbH, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. **In 2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for the innovative Somté recorder product. **In 2007**, Compumedics and Chairman were inducted into the Victorian Manufacturing Hall of Fame. **In 2008** the DWL division received the top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics the Compumedics sales have grown more than 4 fold from \$9 million (1999) to \$38 million (2009). **In 2009** Compumedics was awarded a design award for its GRAEL™ PSG/EEG premium laboratory based product. www.compumedics.com